Colin Tristram
Colin brings to Bioconnexions Consulting Ltd a wealth of commercial and clinical knowledge given his experience and connections within the IVD field from the last fifteen years. Colin studied Medical Microbiology at the University of Newcastle upon Tyne with a specific interest in immunology. He subsequently joined the expanding R&D hybridoma team at Novocastra Laboratories Ltd as a Research Associate helping to develop the range of monoclonal antibodies. As part of Colin’s MSc he studied Her2 in breast cancer and breast cancer cell lines looking at differences in expression of internal and external domains. As a consequence of this work he developed in-house procedures for the processing of formalin fixed paraffin embedded cell lines used as immunohistochemical controls. These were subsequently adopted by various laboratory External Quality Assurance Schemes, namely The UK National External Quality Assurance Scheme for Immunocytochemisty and In-situ hybridisation (UKNEQAS-ICC & ISH).

Following the acquisition of Novocastra Laboratories Ltd by Vision BioSystems Ltd, Colin joined the commercial team expanding the sales of monoclonal antibodies and the Bond automated IHC/ISH platform throughout the UK, Europe and USA. As a consequence Colin developed a wide network of pathologists and researchers in many of the top hospitals and institutes enabling him to develop a Key Opinion Leader program and company publication reAGENTS.

After the acquisition of Vision Biosystems Ltd by the Danaher corporation Colin created the Innovation department at the Newcastle Leica Biosystems facility. The department was responsible for the qualification of projects from a clinical and commercial perspective prior to any R&D work. Over this period there was the development of class I and class III devices and wider collaborations with academics, clinicians and other companies within the biotech industry. Colin was instrumental in developing an Ideation process that worked for an IVD development work stream within the Danaher Business Systems Accelerated Development Process (APD).

As well as being a member of the Pathology Society of Great Britain and Ireland, Colin has previously been an assessor for UKNEQAS. Additionally, since 2010 Colin has been a Consultant and Guest Lecturer for the University of Newcastle upon Tyne at the Graduate School, Faculty of Medicine.

Colin Tristram
Colin Tristram
• 2012 to date
Director, Bioconnexions Consulting Ltd.

• 2007-2012
Head of Innovation, Leica Microsystems (acquired Vision Biosystems), Newcastle.

• 2006-2007
Market Development Manager, Vision Biosystems, Newcastle.

• 2005-2006
Corporate Accounts Manager - Europe, Vision Biosystems, Newcastle.

• 2004-2005
Technical Specialist, Vision Biosystems (acquired Novocastra), Newcastle.

• 1999-2004
Research Associate, Novocastra Laboratories Ltd, Newcastle

Colin Tristram
Colin Tristram
• Chapter 6. Standard Reference Material: Cell Lines Development and Use of Reference Cell Lines as Standards for External Quality Assurance of HER2 IHC and ISH Testing. In Taylor C, Shi S (eds.) Jasani B, Reid V, Tristram C, Walker J, Scorer P, Morgan M, Bartlett J, Ibrahim M, Miller K Antigen Retrieval Immunohistochemistry Based Research and Diagnostics. 1st ed Hobeken, NJ: Wiley-Blackwell; 2010. p101-122.

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms. Grimwade LF, Happerfield L, Tristram C, McIntosh G, Rees M, Bench AJ, Boyd EM, Hall M, Quinn A, Piggott N, Scorer P, Scott MA, Erber WN. Br J Haematol. 2009 Nov;147(4):495-506.

Experimental validation of peptide immunohistochemistry controls. Bogen SA, Vani K, McGraw B, Federico V, Habib I, Zeheb R, Luther E, Tristram C, Sompuram SR. Appl Immunohistochem Mol Morphol. 2009 May;17(3):239-46.

The mouse tumor cell lines EL4 and RMA display mosaic expression of NK-related and certain other surface molecules and appear to have a common origin. Gays F, Unnikrishnan M, Shrestha S, Fraser KP, Brown AR, Tristram CM, Chrzanowska-Lightowlers ZM, Brooks CG. J Immunol. 2000 May 15;164(10):5094-102.

Colin Tristram